Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Their improved stability and efficacy are exemplified by successful and rapid launch of mRNA vaccines, as well as marketed siRNA drug product. Beyond infectious diseases, RNA-LNPs show promise in ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

These findings are in line with a Danish study that reported prolonged anti-spike antibody persistence following vaccination with a third vaccine dose of BNT162b2 or mRNA-1273 (24). Furthermore, ...

doi: 10.1016/j.lanepe.2021.100208 Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection ...

AI-generated image of cancer being attacked by an mRNA vaccine. In the midst of the COVID-19 pandemic, scientists raced to develop vaccines in record time. The first reliable vaccines, using ...

The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030.